Stage
No active trials
Next date
None yet
Trials
0 active
1 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- Tested for
- Postherpetic Neuralgia
- Main trialPhase 1
- “This is a single-center, randomized, single-dose, active-controlled study in healthy male and female subjects. The study will enroll subjects to evaluate the PK of 3 dose strengths (50 mg, 100 mg and 200 mg) of GTX-101 compared to Subcutaneous injection in healthy adult subjects. Blood samples for PK assessments will be collect at specified time points. Safety assessments will also be performed throughout the study.”In the company’s words, NCT05517486 on ClinicalTrials.gov
- Other names
- Bupivacaine HCl metered spray
Other drugs for Postherpetic Neuralgia
- Pregabalin XRBrainfarma Industria Química e Farmacêutica S/A · Phase 3
- HL-1186Shanghai Yidian Pharmaceutical Technology Development Co., Ltd. · Phase 2
- Y-4 tablesNeurodawn Pharmaceutical Co., Ltd. · Phase 2
Coming up0
No dates coming up.
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Unknown | 21 Aug 2022 | Single-dose to Evaluate the Pharmacokinetics of GTX-101 and Subcutaneous Injectable Bupivacaine in Healthy Subjects |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026